Aqr Capital Management LLC Iovance Biotherapeutics, Inc. Transaction History

Aqr Capital Management LLC

$71.5 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$7.78 - $14.19 $221,994 - $404,897	-28,534 Reduced 71.32%	11,477 $92,000
Q1 2024 May 15, 2024	BUY	$7.59 - $17.47 $303,683 - $698,992	40,011 New	40,011 $592,000
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $191,205 - $284,214	34,576 Added 69.5%	84,325 $515,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $10.0 $279,589 - $497,490	49,749 New	49,749 $317,000
Q2 2021 Aug 16, 2021	SELL	$16.33 - $33.07 $555,579 - $1.13 Million	-34,022 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$28.67 - $52.59 $145,557 - $266,999	-5,077 Reduced 12.98%	34,022 $1.06 Million
Q4 2020 Feb 16, 2021	BUY	$28.04 - $50.26 $243,639 - $436,709	8,689 Added 28.57%	39,099 $1.81 Million
Q3 2020 Nov 16, 2020	SELL	$27.75 - $36.3 $2.2 Million - $2.88 Million	-79,292 Reduced 72.28%	30,410 $987,000
Q2 2020 Aug 17, 2020	BUY	$27.21 - $41.0 $1.16 Million - $1.74 Million	42,489 Added 63.22%	109,702 $3.01 Million
Q1 2020 May 15, 2020	BUY	$19.54 - $38.85 $476,013 - $946,424	24,361 Added 56.85%	67,213 $2.01 Million
Q4 2019 Feb 14, 2020	BUY	$17.95 - $29.41 $316,907 - $519,233	17,655 Added 70.07%	42,852 $1.19 Million
Q3 2019 Nov 14, 2019	BUY	$17.99 - $26.0 $453,294 - $655,122	25,197 New	25,197 $459,000
Q1 2019 May 14, 2019	SELL	$8.41 - $11.26 $282,348 - $378,031	-33,573 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$7.51 - $11.93 $98,523 - $156,509	-13,119 Reduced 28.1%	33,573 $297,000
Q3 2018 Nov 15, 2018	BUY	$11.25 - $17.7 $82,046 - $129,086	7,293 Added 18.51%	46,692 $525,000
Q2 2018 Aug 14, 2018	BUY	$12.45 - $16.95 $490,517 - $667,813	39,399 New	39,399 $504,000

Others Institutions Holding IOVA

# of Institutions

314

Shares Held

241M

Call Options Held

3.77M

Put Options Held

1.7M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.46B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.

Account